2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
出版信息
Clin Mol Hepatol. 2018 Sep;24(3):169-229. doi: 10.3350/cmh.2018.1004. Epub 2018 Aug 10.
Abstract
摘要
相似文献
1
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
Clin Mol Hepatol. 2018 Sep;24(3):169-229. doi: 10.3350/cmh.2018.1004. Epub 2018 Aug 10.
2
A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
Eur J Gastroenterol Hepatol. 2019 Mar;31(3):382-388. doi: 10.1097/MEG.0000000000001299.
3
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Lancet Gastroenterol Hepatol. 2016 Oct;1(2):97-104. doi: 10.1016/S2468-1253(16)30015-2. Epub 2016 Jul 25.
4
Sofosbuvir Causing Diabetes Mellitus: Is there a Link?
J Coll Physicians Surg Pak. 2018 May;28(5):414. doi: 10.29271/jcpsp.2018.05.414.
5
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
Orv Hetil. 2015 May 24;156(21):841-8. doi: 10.1556/650.2015.30177.
6
Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.
J Viral Hepat. 2018 Dec;25(12):1501-1506. doi: 10.1111/jvh.12983. Epub 2018 Sep 11.
7
Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
PLoS One. 2018 Oct 11;13(10):e0205600. doi: 10.1371/journal.pone.0205600. eCollection 2018.
8
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
J Med Virol. 2020 Feb;92(2):210-218. doi: 10.1002/jmv.25602. Epub 2019 Oct 16.
9
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
Liver Int. 2016 Jan;36 Suppl 1:47-57. doi: 10.1111/liv.13027.
10
Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
Clin Infect Dis. 2018 Jan 6;66(2):289-292. doi: 10.1093/cid/cix787.
引用本文的文献
1
Aetiology of chronic liver disease is a valuable factor for stratifying adverse outcomes of acute decompensation: prospective observational study.
Ann Med. 2025 Dec;57(1):2428431. doi: 10.1080/07853890.2024.2428431. Epub 2025 Jan 24.
2
Toward hepatitis C virus elimination using artificial intelligence.
Clin Mol Hepatol. 2024 Apr;30(2):147-149. doi: 10.3350/cmh.2024.0135. Epub 2024 Feb 23.
3
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.
J Liver Cancer. 2023 Mar;23(1):1-120. doi: 10.17998/jlc.2022.11.07. Epub 2022 Dec 9.
4
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.
Korean J Radiol. 2022 Dec;23(12):1126-1240. doi: 10.3348/kjr.2022.0822.
5
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.
Clin Mol Hepatol. 2022 Oct;28(4):583-705. doi: 10.3350/cmh.2022.0294. Epub 2022 Oct 1.
6
Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study.
World J Gastroenterol. 2022 Aug 14;28(30):4182-4200. doi: 10.3748/wjg.v28.i30.4182.
7
Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study.
BMC Med. 2022 Jan 24;20(1):18. doi: 10.1186/s12916-021-02215-x.
8
Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea.
J Korean Med Sci. 2021 Nov 29;36(46):e308. doi: 10.3346/jkms.2021.36.e308.
9
Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study.
PLoS One. 2021 Aug 3;16(8):e0255624. doi: 10.1371/journal.pone.0255624. eCollection 2021.
10
Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
Pharmacol Res Perspect. 2021 Aug;9(4):e00811. doi: 10.1002/prp2.811.
本文引用的文献
1
Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series [J Hepatol 73 (2020) 1170-1218].
J Hepatol. 2023 Feb;78(2):452. doi: 10.1016/j.jhep.2022.10.006. Epub 2022 Dec 1.
2
The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment.
Hepatol Commun. 2017 Jun 22;1(6):538-549. doi: 10.1002/hep4.1060. eCollection 2017 Aug.
3
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
J Gastroenterol. 2018 Apr;53(4):557-565. doi: 10.1007/s00535-017-1391-5. Epub 2017 Sep 25.
4
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
Lancet Infect Dis. 2017 Oct;17(10):1062-1068. doi: 10.1016/S1473-3099(17)30496-6. Epub 2017 Aug 14.
5
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
6
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
Hepatology. 2017 Oct;66(4):1083-1089. doi: 10.1002/hep.29256. Epub 2017 Aug 26.
7
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study.
Dig Liver Dis. 2017 Sep;49(9):1022-1028. doi: 10.1016/j.dld.2017.03.025. Epub 2017 Apr 8.
8
Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
Ann Intern Med. 2017 Jun 6;166(11):792-798. doi: 10.7326/M17-0377. Epub 2017 Apr 25.
9
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
J Hepatol. 2017 Aug;67(2):263-271. doi: 10.1016/j.jhep.2017.03.039. Epub 2017 Apr 13.
10
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Gastroenterology. 2017 Jul;153(1):113-122. doi: 10.1053/j.gastro.2017.03.047. Epub 2017 Apr 5.
Zotero 插件